Diagnostic value of ten systematic TRUS-guided prostate biopsies

Current prostate cancer detection methods rely heavily on transrectal ultrasound-guided biopsy. While standard protocols use six biopsy cores, some researchers argue that more cores may improve detection rates. Prior studies have shown that increasing the number of biopsy cores can slightly increase cancer detection. However, the exact benefit of adding more cores remains unclear. No prior work had resolved whether more cores lead to better outcomes without increasing complications. This uncertainty drove the need for a more detailed investigation. Researchers wanted to test if ten biopsy cores would improve cancer detection. They also wanted to assess whether this approach increases complications. The study aimed to address these questions with a systematic approach.

This study aimed to assess whether increasing the number of biopsy cores from six to ten improves prostate cancer detection rates. The researchers focused on patients with elevated PSA or abnormal digital rectal exams. They hypothesized that more cores might capture more cancerous tissue. The study also aimed to evaluate the safety of the ten-core protocol. Complication rates were a key concern. The researchers wanted to avoid unnecessary procedures if no benefit was found. They sought to determine the optimal number of biopsy cores for detection. Their goal was to provide evidence for clinical guidelines on prostate biopsy protocols.

The study involved 162 patients undergoing transrectal ultrasound-guided biopsy. Each patient received ten biopsy cores: five from each lobe. The standard three cores were supplemented with two additional cores at the same angle and plane. The researchers used transrectal ultrasound for guidance. They recorded complication rates and cancer detection outcomes. All biopsies followed a consistent protocol. The team compared results to standard six-core protocols. They analyzed data for overall cancer detection and PSA subgroups. The study was prospective and consecutive to ensure unbiased sampling.

Prostate cancer was detected in 40.1% of the 162 patients. The complication rate was 1.85%, indicating a low risk of adverse events. The ten-core protocol improved cancer detection by 3.1% overall. In patients with PSA ≤10 ng/ml, the improvement was 4.9%. This suggests the protocol is more effective in this subgroup. The study found no significant benefit in increasing cores beyond ten. The additional cores did not alter the biopsy angle or sampling zone. The results suggest that more cores do not always mean better detection.

The ten-core protocol improved cancer detection by 3.1% compared to standard methods. The greatest benefit was seen in patients with PSA ≤10 ng/ml. The complication rate remained low at 1.85%. The study did not find a significant advantage in using more than ten cores. The researchers proposed that increasing cores without changing the angle or zone does not improve detection. They suggested that the ten-core protocol is a reasonable option for some patients. The findings support the use of ten cores in specific clinical scenarios. The authors emphasized the need for further studies to confirm these results.